Tecentriq (atezolizumab)

Non-small cell lung cancer (NSCLC) in adult patients whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs) and do not have EGFR or ALK genomic tumour aberrations, monotherapy for adjuvant treatment following resection and platinum-based chemotherapy, Stage II to IIIA (per the American Joint Committee on Cancer [AJCC], 7th edition)